NACDS expresses pharmacy’s commitment to patient safety in House Panel testimony
ALEXANDRIA, Va. — Written testimony submitted by the National Association of Chain Drug Stores underscored chain pharmacies’ commitment to patient safety as part of the next Prescription Drug User Fee Act reauthorization, and emphasized that community pharmacist-provided services help improve health outcomes without the introduction of unproven technologies.
NACDS submitted the testimony to the U.S. House of Representatives Energy and Commerce Subcommittee on Health ahead of Thursday’s hearing, titled “FDA User Fees 2012: Hearing on Issues Related to Accelerated Approval, Medical Gas, Antibiotic Development and Downstream Pharmaceutical Supply Chain.”
NACDS supports several drug safety reforms included in the proposed PDUFA reauthorization, including the use of drug industry fees to review drug applications for sound-alike proprietary names and factors that could contribute to the likelihood of medication errors, such as unclear label language or package designs.
NACDS also supports the proposal to standardize Risk Evaluation and Mitigation Strategies and further incorporate these risk mitigation plans into the healthcare system. As Congress considers the REMS program, the U.S. Food and Drug Administration should include the development of methodologies to assess the effectiveness of REMS and obtain pharmacy input, as these strategies could impact drug store operations, according to NACDS.
“NACDS and the chain pharmacy industry are committed to partnering with policy-makers and the supply chain stakeholders on viable effective strategies to enhance the safety and security of the U.S. prescription drug distribution supply chain,” NACDS stated in the written testimony for the hearing record. “Our members have invested significant resources and efforts toward this goal, including changes in purchasing practices and actively supporting state legislation that strengthened the supply chain integrity. Nothing is more important to our industry than the health and safety of our patients.”
NACDS emphasized in the testimony that the U.S. drug supply chain is proven safe — if not the safest in the world. Chain pharmacy has supported the development of state-level chain of custody “pedigrees” for medicines distributed outside normal distribution channels, which have demonstrated some marked improvements in supply chain security. However, premature drug “track and trace” models unnecessarily would increase healthcare costs while imposing burdensome technologies that have not demonstrated an ability to enhance supply chain security, NACDS noted.
“As lawmakers, we urge you to consider approaches that are feasible and workable for the supply chain, and to recognize the importance of not requiring untested costly mandates such as a prescription drug ‘track and trace’ system for supply chain stakeholders,” NACDS stated in the written testimony. “Such requirements would add billions in additional costs to the healthcare system and take time and resources away from pharmacies’ ability to provide pharmacy services to their patients.”
Underscoring NACDS and chain pharmacies’ commitment to drug safety, NACDS and several of its members joined the Pharmaceutical Distribution Security Alliance and support many of its policy recommendations, including the adoption of uniform federal wholesale drug distributor licensure requirements to help ensure consistency in regulations across the country and prevent bad actors from avoiding stringent laws by crossing state lines. NACDS also supports the PDSA proposal to implement lot-level tracing, and is providing recommended edits to the alliance’s policy Discussion Draft to address various concerns.
Separately, community pharmacist-provided medication therapy management services help patients understand their medications and avoid costly complications. Proper reimbursement of pharmacists for providing MTM services could further incorporate this counseling into the healthcare delivery system to improve patient safety while reducing costs.
NACDS also supports the development of a registry of safe online pharmacies to help consumers distinguish between legitimate pharmacy websites and illegitimate drug dispensers that often provide adulterated medicines to patients.
Further, NACDS supports the FDA’s development of a “one document solution” to replace the multiple existing drug information inserts, which are duplicative, incomplete and difficult to understand. The creation of a single patient medication information document, which NACDS had called for, could help ensure that an accurate, comprehensible and balanced assessment of drug risks and benefits are communicated to patients, NACDS stated.
No comments found
Prime Therapeutics, Merck KGaA subsidiary enter contractual agreement over MS drug
ST. PAUL, Minn. — A pharmacy benefit manager and the U.S. subsidiary of a German drug maker have made a deal concerning a drug for multiple sclerosis.
Prime Therapeutics and EMD Serono, part of German drug maker Merck KGaA, said the deal for the drug Rebif (interferon beta-1a) would bring the first outcomes-based rebate contract for a multiple sclerosis drug to Prime’s CareCentered Contracting program. The contract stipulates that EMD Serono will pay rebates to Prime if patients on Rebif have a higher overall total cost to their plans than patients on a different MS drug or if the medication adherence rate remains above a specified level.
"With more than 57% of the direct healthcare costs to treat MS in the United States related to drug expenses, it is important to focus on medication adherence and cost effectiveness to ensure the greatest health benefit for each dollar spent," Prime SVP cost of care Peter Wickersham said. "Our CareCentered Contract with EMD Serono goes beyond outcomes to do just that. It includes the total cost of care component, inclusive of medical and pharmacy costs and medication adherence."
No comments found
Drug price inflation outpaces general inflation, AARP study finds
WASHINGTON — Prices for generic drugs may be dropping, but increases in branded and specialty drug prices have offset those decreases, according to a new study.
The study, conducted by AARP’s Public Policy Institute, found that the cumulative change in drug prices from 2005 to 2009 was almost double the rate of inflation. As a result, the average annual cost of drug therapy continued to rise.
The study was based on examinations of retail prices for the 514 drugs most used by Medicare beneficiaries. In 2009, while the rate of general inflation was -0.3%, the drugs increased in price by an average of 4.8%. Branded drugs increased in price by 8.3%, while specialty drugs rose by 8.9% and generic drugs decreased by 7.8%.
"For the people who rely on these drugs, such relentless price increase have serious implications," AARP SVP public strategy Cheryl Matheis said. "Despite price reductions for generics, it’s evident that the considerable increases in brand name and specialty drug prices are still leaving Americans with overall costs that are growing far faster than the rate of inflation."
For the 469 drugs on the market since the end of 2004, prices increased by 25.6% from 2005 to 2009, while the general inflation rate was 13.3%. Consumers taking drugs to treat chronic diseases found that their average annual cost increased from $2,160 to $3,168.
My anger grows every day I work seeing Medicaid patients pick up these medications for a little bit of nothing when we have to call doctors and switch prescribed medications to something cheaper for working (insured) patients who can't afford to pay for these even if the second choice medication may not be as effective for them.